[go: up one dir, main page]

WO2022033459A9 - Utilisation de médicament double non-oncologique dans la préparation d'une composition pharmaceutique pour le traitement du cancer - Google Patents

Utilisation de médicament double non-oncologique dans la préparation d'une composition pharmaceutique pour le traitement du cancer Download PDF

Info

Publication number
WO2022033459A9
WO2022033459A9 PCT/CN2021/111714 CN2021111714W WO2022033459A9 WO 2022033459 A9 WO2022033459 A9 WO 2022033459A9 CN 2021111714 W CN2021111714 W CN 2021111714W WO 2022033459 A9 WO2022033459 A9 WO 2022033459A9
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
preparation
drugs
treating cancers
oncological drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/111714
Other languages
English (en)
Chinese (zh)
Other versions
WO2022033459A1 (fr
Inventor
萧乃文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shih Kuei Chung
Original Assignee
Shih Kuei Chung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shih Kuei Chung filed Critical Shih Kuei Chung
Publication of WO2022033459A1 publication Critical patent/WO2022033459A1/fr
Publication of WO2022033459A9 publication Critical patent/WO2022033459A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un médicament double non-oncologique dans la préparation d'une composition pharmaceutique pour le traitement du cancer. Le médicament double non-oncologique comprend deux médicaments choisis dans le groupe constitué par la paroxétine, le pyrvinium, le niclosamide, la zidovudine, l'albendazole, la lovastatine, l'auranofine, le carburmazole, la dexaméthasone, le flubendazole, la lovastatine, la pyriméthamine, le bésylate d'amlodipine, l'azelnidipine, le disulfirame, le fasudil ou un diphosphonate tel que le clodronate. La composition pharmaceutique inhibe efficacement le taux de survie des cellules cancéreuses à 0,5 ou moins et le médicament combiné présente une valeur synergique de 1,3 ou plus.
PCT/CN2021/111714 2020-08-10 2021-08-10 Utilisation de médicament double non-oncologique dans la préparation d'une composition pharmaceutique pour le traitement du cancer Ceased WO2022033459A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063063665P 2020-08-10 2020-08-10
US63/063,665 2020-08-10

Publications (2)

Publication Number Publication Date
WO2022033459A1 WO2022033459A1 (fr) 2022-02-17
WO2022033459A9 true WO2022033459A9 (fr) 2022-04-21

Family

ID=80246910

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2021/111714 Ceased WO2022033459A1 (fr) 2020-08-10 2021-08-10 Utilisation de médicament double non-oncologique dans la préparation d'une composition pharmaceutique pour le traitement du cancer
PCT/CN2021/111752 Ceased WO2022033465A1 (fr) 2020-08-10 2021-08-10 Composition pharmaceutique de niclosamide et disulfirame ayant un effet anticancéreux synergique et son utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/111752 Ceased WO2022033465A1 (fr) 2020-08-10 2021-08-10 Composition pharmaceutique de niclosamide et disulfirame ayant un effet anticancéreux synergique et son utilisation

Country Status (2)

Country Link
TW (2) TW202214244A (fr)
WO (2) WO2022033459A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116999552A (zh) * 2022-04-29 2023-11-07 中山大学 一种含有金诺芬和多硫化合物的组合物及其应用
TWI854801B (zh) * 2022-08-29 2024-09-01 石貴中 醫藥組合物及其用途
PL442757A1 (pl) * 2022-11-08 2024-05-13 Zakład Badawczo-Produkcyjny Syntex Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna zawierająca auranofinę, jej zastosowanie oraz produkt leczniczy zawierający tą kompozycję
TW202502312A (zh) * 2023-07-14 2025-01-16 石貴中 組合物及其用於動物之用途
CN116808176B (zh) * 2023-08-30 2023-12-05 上海彗天锦泽生物医学科技有限公司 一种基于免疫检查点阻断的抗肿瘤药物组合物及其应用
WO2025058297A1 (fr) * 2023-09-12 2025-03-20 국립암센터 Composition pour la prévention ou le traitement du cancer, comprenant un inhibiteur de stat3 et du niclosamide
CN118059099B (zh) * 2024-04-19 2024-06-14 四川大学华西医院 帕罗西汀联合asct2抑制剂用于制备治疗肝癌的药物中的应用及药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038022A1 (en) * 2001-03-26 2005-02-17 Unisearch Limited Method for treatment of cancer and compositions for use therein
CN101106992A (zh) * 2005-01-18 2008-01-16 伊姆索公司 新颖的喹啉鎓盐和衍生物
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101254183A (zh) * 2008-03-19 2008-09-03 中国科学院广州生物医药与健康研究院 氯硝柳胺或其药学上可接受的盐的新应用
GB201020860D0 (en) * 2010-12-09 2011-01-26 Univ Wolverhampton Disulfiram formulation and uses thereof
WO2012079232A1 (fr) * 2010-12-15 2012-06-21 Lai Hung-Cheng Composés utilisés pour traiter le cancer et utilisation associée compounds used for treating cancer and the use thereof
EA032775B1 (ru) * 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
US20160136123A1 (en) * 2013-06-14 2016-05-19 Vojo P. Deretic Treatment of autophagy-related disorders
CN105792823B (zh) * 2013-11-01 2019-11-12 皮特尼制药股份有限公司 治疗恶性肿瘤的药物组合
WO2015077411A1 (fr) * 2013-11-20 2015-05-28 Biommune Technologies Inc. Composés de curcuphénol pour accroître l'expression du cmh-i
TW201615195A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 阿那格雷藥物應用於癌症治療
US10722505B2 (en) * 2014-10-31 2020-07-28 Genoscience Pharma Substituted 2,4 diamino-quinoline as new anticancer agents
EP3285753A1 (fr) * 2015-04-22 2018-02-28 CeMM - Forschungszentrum für Molekulare Medizin GmbH Combinaison d'un anti-androgène avec un antagoniste de la vitamine k ou avec un inhibiteur de la gamma-glutamyl carboxylase pour la thérapie d'un cancer positif aux récepteurs des androgènes
CN108366987A (zh) * 2015-04-30 2018-08-03 河谷控股Ip有限责任公司 通过致畸药物化合物对患者进行治疗
EP3311843A1 (fr) * 2016-10-13 2018-04-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Composition comprenant du diéthyldithiocarbamate de sodium et de la cyclodextrine
CN106727479B (zh) * 2016-11-18 2019-02-22 南京医科大学第二附属医院 多取代萘衍生物在制备抗肿瘤血管生成药物中的应用及药物组合物
CN111417730A (zh) * 2017-11-20 2020-07-14 托雷莫治疗股份公司 诊断方法
CN108904510A (zh) * 2018-07-13 2018-11-30 北京大学 地塞米松用于抑制或治疗胰腺癌的用途

Also Published As

Publication number Publication date
WO2022033465A1 (fr) 2022-02-17
TW202214244A (zh) 2022-04-16
TW202214245A (zh) 2022-04-16
WO2022033459A1 (fr) 2022-02-17

Similar Documents

Publication Publication Date Title
WO2022033459A9 (fr) Utilisation de médicament double non-oncologique dans la préparation d&#39;une composition pharmaceutique pour le traitement du cancer
Herrstedt et al. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis
TW200503775A (en) Pharmaceutical composition and method for treating
NZ595127A (en) Stable pharmaceutical composition for atherosclerosis
WO2005039499A3 (fr) Pellicules a desintegration rapide destinees a l&#39;administration d&#39;agents pharmaceutiques ou cosmetiques
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
NZ592971A (en) Solid dosage forms of bendamustine
PH12022553235A1 (en) Compound for the treatment of coronaviral infections
WO2008142572A3 (fr) Formulation de comprimé à libération contrôlée contenant de l&#39;aluminométasilicate de magnésium
WO2011159100A2 (fr) Composition pharmaceutique anticancéreuse
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
BR112012009857A2 (pt) composições farmacêuticas sólidas contendo um inibidor de integrase
WO2010044097A3 (fr) Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci
MX2009006699A (es) Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos.
CA3258707A1 (fr) Composition pharmaceutique pour traiter et résister à la coagulation sanguine, et son utilisation
UA89349C2 (uk) Таблетка без покриття, яка містить оланзапін, та спосіб її одержання
WO2007103931A3 (fr) Composition nanofluidisee b-12 et procede pour le traitement de l&#39;anemie pernicieuse
GB2595406A (en) Pharmaceutical composition containing acetominophen and ibuprofen
WO2020190900A8 (fr) Formulations pharmaceutiques à base d&#39;abiratérone et d&#39;oligomère cyclique et procédés de formation et d&#39;administration de celles-ci
WO2012143624A3 (fr) Dérivés de l&#39;acadésine, produits et compositions les comprenant, leurs utilisations thérapeutiques et leurs procédés de synthèse
MX2023000479A (es) Composiciones farmaceuticas orales hinchables.
WO2002056867A3 (fr) Composition pharmaceutique a liberation lente contenant des antibiotiques $g(b)-lactame a efficacite therapeutique amelioree
CA2641571A1 (fr) Traitement de l&#39;arthrose
WO2010064817A3 (fr) Nouveaux composés à base de coumarine, procédé de préparation de ces derniers et compositions pharmaceutiques inhibant la résistance pléiotrope contenant ces nouveaux composés en tant qu&#39;ingrédients actifs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21855511

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21855511

Country of ref document: EP

Kind code of ref document: A1